Ablation, Atrial Fibrillation, Atrial Flutter, Cardioversion, Thrombus; Embolism, Transesophageal Echocardiography
Conditions
Keywords
Atrial fibrillation, Atrial Flutter, Transesophageal echocardiography, Ablation, Cardioversion, Thrombus; Embolism
Brief summary
The aim of the study is to assess the prevalence of left atrial thrombus in patients with atrial fibrillation (AF) or atrial flutter (AFI), in whom transesophageal echocardiography is performed before AF/AFl cardioversion or ablation.
Detailed description
Atrial fibrillation (AF) and atrial flutter (AFI) increase the risk of thromboembolic events by promoting clot formation in the left atrium (LA). Transesophageal echocardiography (TEE) is routinely used to exclude the presence of an LA thrombus before AF/AFI ablation or cardioversion. So far, it has not been established what is the optimal combination of noninvasive parameters for thromboembolic risk stratification in this setting. The present study is aimed to compare the prevalence of LA thrombus in patients on different anticoagulant regimens, identify predictors of LA thrombus and validate the newly developed CHA2DS2-VASc-AF-GFR score (and to compare its predictive value in LA thrombus identification with those of the CHA2DS2-VASc and the CHADS2 scores). The study protocol all patients with AF or AFl in whom TEE will be performed (to assess their eligibility for cardioversion or ablation), hospitalized in a participating center during study period.
Interventions
DIAGNOSTIC_TESTTransesophageal echocardiography
Transesophageal echocardiography will be used to exclude the presence of an LA thrombus before AF/AFI ablation or cardioversion.
Sponsors
Medical University of Warsaw
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Inclusion criteria
* All patients with AF or AFl in whom TEE will be performed (to assess their eligibility for cardioversion or ablation), hospitalized in a participating center during study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Assessment of the prevalence of LA thrombus in patients with AF/AFI, in whom TEE is performed before AF/AFl cardioversion or ablation. | One day |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of the prevalence of LA thrombus in patients on different anticoagulant regimens. | Up to 12 months |
| Identification of the predictors of LA thrombus. | Up to 12 months |
| Validation of the the newly developed CHA2DS2-VASc-AF-GFR score (and to compare its predictive value in LA thrombus identification with those of the CHA2DS2-VASc and the CHADS2 scores). | Up to 12 months |
Countries
Poland
Outcome results
None listed